Skip to content

Vitamin D for Chronic Sinusitis

A Randomized, Clinical Trial of a Novel Immunotherapy for Chronic Sinusitis: Vitamin D

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01007799
Enrollment
30
Registered
2009-11-04
Start date
2009-11-30
Completion date
2011-09-30
Last updated
2016-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Sinusitis

Brief summary

The purpose of this study is to examine if vitamin D improves the symptoms of chronic sinusitis.

Interventions

DIETARY_SUPPLEMENTvitamin D placebo

12 weeks of placebo

DIETARY_SUPPLEMENTVitamin D

12 weeks supplementation based on serum vitamin D levels

Sponsors

University of Chicago
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* African American (4 grandparents with AA ancestry) * Age\>18 years * Diagnosis of chronic sinusitis

Exclusion criteria

* Women of childbearing potential not utilizing contraception * Subjects with contraindications to vitamin D therapy * History of nephrolithiasis, hypercalcemia, sarcoidosis, recent (3 month) hospitalization * Use of immunosuppressants/medications that interfere with vitamin D metabolism (e.g., phenytoin and carbamazepine) * Malignancy * Kidney, gastrointestinal, or liver disorders * Immunodeficiency * Morbid obesity (BMI\>35 kg/m2) * Changes to medications for 6 months prior to study entry

Design outcomes

Primary

MeasureTime frame
score on the Sinonasal Outcome Test-22 (SNOT-22)study onset, mid-point and conclusion

Secondary

MeasureTime frame
Quality of life as measured by SF-36At entry and at completion of study

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026